Effectiveness of preoperative using recombinant human erythropoietin injection in patients undergoing total hip arthroplasty or total knee arthroplasty with anemia

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-15005959

Enrollment

Unknown

Registered

2015-02-03

Start date

2015-03-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End-staged joint diseases

Interventions

A:basic blood management+EPO preoperative 5 days to postoperative 3 days first time 40000U then 10000U one time*8 days

B:Basic blood management+EPO 4000U one time/week preoperative day 21/14/7 the operative day total 4 times (40000U qw*4)

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients receiving total hip arthroplasty/total knee arthroplasty for end-staged joint diseases; 2. Age from 40-70 years with no limitation of gender; 3. For male, the preoperative Hb should be no more than 130g/L. For female, the preoperative Hb should be no more than 115g/L. 4. Patients who volunteered to participate in clinical trials and signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients combined with acute trauma, tumor, severe osteoporosis, other autoimmune diseases and severe muscle contracture deformity around hip/knee; 2. Previous history of neuro-vascular injury, vasculitis and diabetic foot etc; 3. Related thrombosis history, such as pulmonary embolism, thrombosis and deep vein thrombosis in recent three months; 4. Coagulation disorders, bleeding tendency or intraoperative active bleeding; 5. Clear history of iron metabolism disorders; 6. Sever comorbidities in brain cardiovascular system, liver (ALT or AST >2 high limitation of normal value), kidney (BUN >1.5 high limitation of normal value or Cr> 1.5 high limitation of normal value), endocrine, nerve, hematopoietic system or consciousness disorders; 7. Pregnancy or breast-feeding; 8. Allergy to the test drug and human serum albumin, severe allergies, drug or alcohol depedence; 9. Participate in other clinical trials in recent three months; 10. The surgeons believe the patients not suitable for this clinical trial.

Design outcomes

Primary

Measure	Time frame
Hb;	—

Secondary

Measure	Time frame
Hct;RET;perioperative transfusion;ROM of hip/knee;	—

Countries

China

Contacts

Public ContactMa Jun

dr.majun@foxmail.com+86 18980605921

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026